Design, synthesis, molecular dynamics studies and biological evaluations of 4-hydroxy-5-pyrrolinone-3-carbohydrazides as HIV-1 integrase inhibitors
Acquired immune deficiency syndrome (AIDS) diseases despite the efficacy of anti-HIV therapy, remain one of the human's most serious problems. Hence, the introduction of novel anti-HIV agents as first-line therapy is still required. HIV integrase lacking human enzyme homologous is an interestin...
        Saved in:
      
    
          | Main Authors: | Nafiseh Karimi, Amirreza Dowlati Beirami, Rouhollah Vahabpour Roudsari, Zahra Hajimahdi, Afshin Zarghi | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | Elsevier
    
        2024-12-01 | 
| Series: | European Journal of Medicinal Chemistry Reports | 
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772417424000803 | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    5-Bromo-<i>N</i>′-(2-oxoindolin-3-ylidene)furan-2-carbohydrazide        
                          
 by: Nur Pasca Aijijiyah, et al.
 Published: (2024-12-01)
- 
                
                    Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants        
                          
 by: Steven J. Smith, et al.
 Published: (2025-01-01)
- 
                
                    The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir        
                          
 by: Tung Dinh, et al.
 Published: (2024-11-01)
- 
                
                    Exploring Zinc C295 as a Dual HIV-1 Integrase Inhibitor: From Strand Transfer to 3′-Processing Suppression        
                          
 by: Sharif Karim Sayyed, et al.
 Published: (2024-12-01)
- 
                
                    Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV        
                          
 by: Arianna E. Kousari, et al.
 Published: (2024-12-01)
 
       